AstraZeneca boosts US biologics capacity with $2B Maryland expansion

Rhea-AI Filing Summary

AstraZeneca PLC plans to invest $2 billion to expand its manufacturing footprint in Maryland, adding major capacity for cancer, rare and chronic disease medicines. The company will significantly expand its biologics facility in Frederick, nearly doubling commercial manufacturing capacity and supporting 200 new highly skilled jobs and 900 construction roles, with operations expected in 2029. A new clinical manufacturing facility in Gaithersburg will focus on development and clinical supply of innovative molecules, creating 100 new jobs, retaining 400 roles and supporting 1,000 construction-related jobs, and is also expected to be fully operational in 2029.

The investment supports a total of 2,600 jobs across the two Maryland sites and will, for the first time, bring production across AstraZeneca's rare disease portfolio onshore in the US. This is the fourth major US manufacturing investment announced this year and forms part of AstraZeneca's previously announced historic $50 billion commitment to medicines manufacturing and R&D.

Positive

• $2 billion Maryland manufacturing expansion nearly doubles biologics capacity and supports 2,600 jobs across Frederick and Gaithersburg.
• Onshoring rare disease production to the US for the first time strengthens AstraZeneca's stated goal of a more resilient medicines supply chain.
• Part of a historic $50 billion program for manufacturing and R&D, reinforcing long-term commitment to US and global biopharmaceutical infrastructure.

Negative

• None.

Insights

Biopharmaceutical strategy analyst

AstraZeneca commits $2B to expand US biologics and rare disease manufacturing in Maryland.

AstraZeneca is allocating $2 billion to expand its Frederick biologics site and build a new Gaithersburg clinical manufacturing facility. The Frederick expansion is expected to nearly double commercial biologics capacity, including cancer, autoimmune, respiratory and rare disease medicines, with operations targeted for 2029. The Gaithersburg site will develop and supply innovative molecules for clinical trials and is also expected to be fully operational by 2029.

The announcement states the Maryland investment supports 2,600 jobs across retention, new roles and construction, including 300 highly skilled permanent jobs. For the first time, production across the company's rare disease portfolio will be brought onshore in the US, which the company links to strengthening the US medicines supply chain. This move is described as the fourth major US manufacturing investment this year and part of a historic $50 billion global commitment to medicines manufacturing and R&D.

The company notes that both facilities will use AI, automation and data analytics and be built to high environmental standards. The US is described as AstraZeneca's largest market by sales, with more than 25,000 employees and more than 100,000 jobs supported overall, and an estimated $20 billion of value created for the American economy in 2025. Subsequent disclosures may provide more detail on capital phasing and the specific product mix allocated to these new and expanded Maryland facilities.

Form 6-K: How Foreign Companies Report to the SEC →

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of November 2025 

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

AstraZeneca manufacturing investment in Maryland

24 November 2025

AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalysing economic growth

New capacity at AstraZeneca's Frederick and Gaithersburg facilities will accelerate production of cancer, rare and chronic disease medicines

Fourth major US manufacturing investment announced this year, advancing AstraZeneca's historic $50 billion commitment to medicines manufacturing and R&D

AstraZeneca today announces plans to invest $2 billion to expand its long-standing manufacturing footprint in Maryland. This includes a significant expansion of its flagship biologics manufacturing facility in Frederick and construction of a new state-of-the-art facility in Gaithersburg for the development and clinical supply of innovative molecules to be used in clinical trials. The investment will support 2,600 jobs across the two sites in the state including the retention of local roles, construction activity, and the creation of 300 highly skilled jobs. 

The Frederick facility currently produces biologics, a type of medication used across AstraZeneca's portfolio of cancer, auto immune, respiratory and rare disease treatments. The planned expansion will nearly double commercial manufacturing capacity, enabling increased supply of existing medicines and, for the first time, production across the Company's rare disease portfolio.  It will create 200 highly skilled jobs and 900 construction roles and is expected to be operational in 2029.

In parallel, AstraZeneca will build a new clinical manufacturing facility to expand its footprint in Gaithersburg.  The facility, which will be fully operational by 2029, will create an additional 100 jobs, retain 400 roles and support a further 1,000 construction-related jobs.

Both the expanded facility in Frederick and the new facility in Gaithersburg will leverage cutting-edge AI, automation and data analytics and be built to the highest environmental standards.

Maryland Governor, Wes Moore, said: "AstraZeneca's commitment to Maryland speaks to our unique, world-class biotech ecosystem.  This landmark investment affirms our reputation as a global leader in life sciences, while strengthening the U.S. medicine supply chain, accelerating the development of life-saving therapies, and creating hundreds of jobs. We are proud to partner with AstraZeneca to grow our economy and build new pathways to work, wages, and wealth for all." 

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: "Today marks a landmark moment for Maryland and American patients. As the state's largest biopharmaceutical employer, we are deepening our long-standing commitment to Maryland - supporting 2,600 jobs, catalysing economic growth and bringing our extensive rare disease portfolio onshore for the first time. This investment strengthens the resilience of the US medicines supply chain and accelerates access to transformative therapies for patients across America and around the world." 

Today's announcement is part of AstraZeneca's historic $50 billion investment announced in July and follows a series of US commitments over the past six months, including unveiling a new cell therapy manufacturing facility in Rockville, Maryland, a new drug substance manufacturing facility in Virginia and the expansion of the Company's existing manufacturing facility in Coppell, Texas.

The US is AstraZeneca's largest market by sales and is also home to 19 R&D, manufacturing and commercial sites. The Company's US workforce exceeds more than 25,000 people and supports more than 100,000 jobs overall across the country. In 2025, AstraZeneca created approximately $20 billion of overall value to the American economy.

Notes

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 24 November 2025

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary

FAQ

What did AstraZeneca (AZN) announce in its November 2025 Form 6-K?

AstraZeneca announced plans to invest $2 billion to expand manufacturing in Maryland, including enlarging its Frederick biologics facility and building a new clinical manufacturing site in Gaithersburg.

How many jobs will AstraZeneca’s Maryland investment support?

The Maryland investment will support 2,600 jobs across the two sites, including job retention, construction roles and the creation of 300 highly skilled jobs.

What changes are planned for AstraZeneca’s Frederick, Maryland facility?

The Frederick facility will undergo a major expansion that is expected to nearly double commercial manufacturing capacity, add 200 highly skilled jobs and 900 construction roles, and is expected to be operational in 2029.

What will the new Gaithersburg facility do for AstraZeneca?

The Gaithersburg site will be a new clinical manufacturing facility for development and clinical supply of innovative molecules, creating 100 new jobs, retaining 400 roles and supporting 1,000 construction-related jobs, with full operations expected in 2029.

How does this Maryland investment fit into AstraZeneca’s broader spending plans?

The Maryland expansion is the fourth major US manufacturing investment announced this year and forms part of AstraZeneca’s previously announced $50 billion commitment to medicines manufacturing and R&D.

Why is the rare disease portfolio mentioned in AstraZeneca’s 6-K filing?

AstraZeneca states that the Frederick expansion will allow production across its rare disease portfolio in the US for the first time, which it links to strengthening the US medicines supply chain and patient access.

How important is the US market to AstraZeneca according to this report?

The US is described as AstraZeneca’s largest market by sales, with more than 25,000 employees, over 100,000 jobs supported overall, and about $20 billion of value created for the American economy in 2025.